Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

http://www.wikidata.org/entity/Q36018548

about

Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam.Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice.Ceftolozane/Tazobactam.Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.Population Pharmacokinetics and Safety of Ceftolozane-Tazobactam in Adult Cystic Fibrosis Patients Admitted with Acute Pulmonary Exacerbation.Cephalosporins currently in early clinical trials for the treatment of bacterial infections.Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.Ceftolozane/tazobactam for the treatment of complicated urinary tract and intra-abdominal infections.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease Pharmacokinetics and Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.Pharmacokinetics, safety, and tolerability of ceftolozane/tazobactam in healthy Japanese, Chinese, and white subjects.Development of an HPLC Method for the Determination of Ceftolozane/Tazobactam in Biological and Aqueous Matrixes.In Vitro Activity of Ceftolozane-Tazobactam against Multidrug-Resistant Nonfermenting Gram-Negative Bacilli Isolated from Patients with Cystic Fibrosis.Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency.

P2860

Q26747429-CFE5F8DD-4DB4-4B38-9051-EE6358EB166A Q26998883-54820ACE-F0CF-4903-AED0-142F8126E9AA Q27001490-CED964F0-5C54-41CE-AE85-5F52D680BA5B Q28069563-94C59945-61C9-4633-B25C-163127AF81D1 Q33623078-C7237353-5937-4276-AF4E-9BD46F7D59CB Q34057425-3DC0A81A-FF7D-4B34-B3C1-16441B3A4528 Q34299064-AF9E41D5-C660-4EE5-A0E1-599D813CD677 Q34320027-D3078895-FD1B-4A1B-9302-B358E4BCFF13 Q34393008-34B4CDF7-39C3-475D-83FE-53AA31AA991D Q34688710-9955969A-1450-4E18-B892-330B232F9BDC Q35004269-AB306F16-EFC0-4271-BEE7-E7843558C6D9 Q35545954-82136FD0-91FA-48F3-BD1D-0C37F461205C Q35607735-54162B42-DA52-40DB-BB6C-94E143CF2BF1 Q36055019-07B92D4F-1197-4BE2-85EA-2AEEC48C54DA Q36644705-FB52D34E-7A7F-4312-BE68-323B1F1CDCF4 Q36730017-FA92158B-87E0-4097-9351-56594185C0A7 Q36761826-3F78182B-EA83-4AA1-9973-6B083852B086 Q37023118-ECCC8949-4D64-488E-BE06-1BF53C8E5166 Q37055016-A5538FAF-8473-498C-9A16-371104266245 Q37308807-65FBB01F-A602-40A2-9113-5FC25BC879E3 Q37358630-1C8441E7-4276-4BEB-9017-E53F1A0DE202 Q38222497-697D0881-6DC4-42ED-9230-7B6D6FA7FA01 Q38241417-75B50BA7-8223-43B0-92CD-7DB1898D8BB0 Q38296151-9BECF92B-36C2-49C8-A99B-92AE01CE51CC Q38541624-445FBFD1-2C3E-4928-82A1-F19C2CB2CDEE Q38544744-7999C90B-270C-42A7-A381-E13A39380177 Q38648594-D28F3447-2457-45BC-9F4B-2064F443A821 Q38650049-55E1E8BF-A896-4BEC-9CFF-051B789722EF Q38690748-B7626218-7732-4D15-AE93-2AEEDF6FBB70 Q38872130-8B55B4E2-56AD-413B-AE4F-1E1E62382A89 Q38934400-76EBA58D-FD88-4ACC-A3B8-6DCE3F211061 Q38949043-9113EC57-858E-4A1C-A0D9-36A79E994925 Q39037981-398C06DB-FB8C-4325-A768-29C547EB96C0 Q39066154-A506A98B-581B-44C4-8209-35F6A1BEFA19 Q40052714-E76203FA-3AEE-454E-B65A-4EFCF1C092E2 Q40595075-BD646756-F3DB-48AB-8335-281A86213C16 Q40727077-3AE74C36-7778-4726-9A15-B1ACB0B98ABC Q41695599-5BA3999C-B2E8-4FD8-998A-DB0112C2301E Q42237788-AC167E6F-1CA4-430E-B0F0-CEA8EAF77C79 Q47165438-413106DE-0FB5-4CB6-AC37-1641D15BE10A

P2860

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses.

http://www.wikidata.org/entity/Q36018548

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Pharmacokinetics and safety of ...... and multiple ascending doses.

@ast

Pharmacokinetics and safety of ...... and multiple ascending doses.

@en

type

label

Pharmacokinetics and safety of ...... and multiple ascending doses.

@ast

Pharmacokinetics and safety of ...... and multiple ascending doses.

@en

prefLabel

Pharmacokinetics and safety of ...... and multiple ascending doses.

@ast

Pharmacokinetics and safety of ...... and multiple ascending doses.

@en

P1433

Q36018548-A968D097-4E8D-4176-BB7A-2D008C0F450E

P1476

Q36018548-0B0D7F37-4F0A-4958-980F-F7392A6BE65E

P2093

Q36018548-39BF7894-5A01-4626-B9EA-3467888AED02

Q36018548-81DE3B7B-5B54-4141-A6B1-EE95256B3D42

Q36018548-8747A8F8-3A06-4930-B487-AAC647AF68D7

Q36018548-B71E5D2F-CF48-4E1E-BB59-219A8E82EA65

P2860

Q36018548-11DB679C-F3C3-4A52-BBFA-02C74A471A26

Q36018548-1D18804A-0177-4F87-9D25-521C048F4400

Q36018548-488F7250-D186-4A80-AEC3-169CE4894CCA

Q36018548-58C87854-AAD3-40ED-ADD4-4B480DB90966

Q36018548-733BF627-5C2D-432C-B0B7-DDED926B97D0

Q36018548-D87B6B20-DF7F-4A87-81EF-B64215A1B441

Q36018548-DB2B0438-3643-4928-870A-3980540DDD9E

Q36018548-E98296C3-F1D0-4903-8952-3005BB27A2CB

Q36018548-EB95F541-2DA4-4D0A-9818-11601CCF04FA

P304

Q36018548-588D6FA5-507B-4C07-AD74-209106EEE8AE

P31

Q36018548-E0E01B47-5AF0-408D-9B89-7B2FCE2BA993

P356

Q36018548-6C9F134D-7BD1-41E8-9798-25B223A32F39

P407

Q36018548-B49C443C-1C3F-417E-AF0C-949240206D16

P433

Q36018548-4A86BC6A-8D5C-46FA-AD5A-40AC04F068AC

P478

Q36018548-C45E18E2-65C4-4B8B-B5EB-699165D86589

P50

Q36018548-5C0B02FE-ADBC-4BF7-8575-28BCE0C12A83

P577

Q36018548-424E4C06-3949-4612-86BE-9D821089E0FF

P5875

Q36018548-6FA8AA7E-6FD7-4336-B7D7-1EE3DFCA733B

P698

Q36018548-35182EFF-B6E1-4987-9D19-5959E0035343

P932

Q36018548-BA9A93B2-2FC8-4828-83CD-BD90317F4E66

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics and safety of ...... and multiple ascending doses.

@en

P2093

David Benziger

http://www.w3.org/2001/XMLSchema#string

Ellie Hershberger

http://www.w3.org/2001/XMLSchema#string

Ian Friedland

http://www.w3.org/2001/XMLSchema#string

Mymy Trinh

http://www.w3.org/2001/XMLSchema#string

P2860

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

Clinical and economic burden of antimicrobial resistance.

In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae.

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin.

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.

Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.

P304

3086-3091

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.06349-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Benjamin L. Miller

P577

2012-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221982451

http://www.w3.org/2001/XMLSchema#string

P698

22450972

http://www.w3.org/2001/XMLSchema#string

P932

3370713

http://www.w3.org/2001/XMLSchema#string